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Background: Bronchiectasis (BQs) is an uncommon disease with the potential to
cause devastating complications. All patients with BQs have cough and chronic
sputum production that may have a great impact on patient’s quality of life. Upper
airway symptoms are also frequent in patients with BQs. Associations between upper
and lower airways diseases have been demonstrated in allergic rhinitis and asthma,
nasal polyposis and asthma, chronic obstructive lung disease and chronic
rhinosinusitis.
Objective: (1) To investigate the impact of bronchiectasis and nasal symptoms on
quality of life. (2) To evaluate the added impact of nasal polyposis on quality of life
in patients with BQs.
Methods: Sixty patients with bronchiectasis and upper airway symptoms were
included. Patients were evaluated for nasal symptoms, nasal polyp size by
endoscopy, and quality of life using the SF-36 generic questionnaire.
Results: In comparison with the Spanish general population, patients with BQs had
worse scores in all SF-36 domains (Po0.05). Males reported significantly higher
quality of life scores on physical functioning and social functioning than females did.
Although the age, pulmonary function, presence of nasal polyps, upper airway
symptoms, tobacco smoking history, and disease duration was similar between them.
Males with BQs had worse quality of life than males from the Spanish general
population on body pain, general health, and vitality (Po0.05). Females with BQs
had worse quality of life than females from the Spanish general population on
physical function, body pain, general health, vitality, social function, and emotional
role (Po0.05). Nasal polyps were found in 25 (41.6%) of 60 patients with BQs.Elsevier Ltd. All rights reserved.
279 872; fax: +34 932 275 454.
(J.M. Guilemany).
ARTICLE IN PRESS
J.M. Guilemany et al.1998No significant differences were observed on quality of life outcomes between
patients with BQs with and without nasal polyposis.
Conclusion: These results suggest that BQs has a considerable impact on quality of
life while nasal polyposis has no additional impact on the quality of life of patients
with BQs.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Bronchiectasis (BQs) consists of a permanent and
irreversible destruction and dilatation of bronchi
and bronchioles due to retained secretions and
recurrent infections that cause inflammation, ob-
struction, and damage of the lower airway. BQs are
a consequence of a variety of different diseases
where infection and obstruction appears to be the
most important contributory factors. BQs are
frequently associated with cystic fibrosis, primary
ciliary dyskinesia, immunodeficiency, rheumatoid
arthritis, and inflammatory bowel disease.1
Nasal polyposis (NP) is a chronic inflammatory
disease of the nose and sinus mucosa that, despite
differing hypotheses of its cause, remains poorly
understood.2,3 NP can lead to progressive nasal
obstruction, loss of smell, rhinorrhea, and sneez-
ing. NP is frequently associated with asthma and
other pulmonary disorders such as cystic fibrosis,
primary ciliary dyskinesia, and aspirin sensitivity.4,5
BQs is a disease with the potential to cause
devastating complications. The patients with BQs
have cough and chronic sputum production that
have a great impact on patient’s quality of life
(QoL). Most patients undergo slow and progressive
health deterioration over decades. It can have
detrimental effects on physical, psychological, and
social aspects of the patient0s life, significantly
worsening the patient’s QoL. The lung function
does not reflect the impact of the disease in the
patient0s health status and thus should be supple-
mented using QoL questionnaires.6 However, the
impact of BQs to patients’ general health status has
not been reported for the Spanish patients. Gen-
erally, there are two major types of QoL instru-
ments used in clinical trials: specific and generic.
Specific questionnaires are usually focused on one
particular area such as a disease state, a selected
population, or a certain function or problem. The
St. George Respiratory Questionnaire (SGRQ) has
been used to assess the QoL in patients with
asthma, COPD, a1-antitrypsin deficiency, intersti-
cial lung diseases and BQ.7
Generic QoL questionnaires are also available
and may be administrated to any individual,thereby making it possible to assess the burden of
illness in different conditions. The Short Form-36
Health Survey (SF-36) is the most widely used
generic instrument to measure health status. This
questionnaire has been recently adapted for the
Spanish-speaking general population according to
the International Quality of Life Assessment (IQO-
LA) project showing a good reproducibility and
validity.8–10
The aims of this study were: (1) to investigate
the impact of BQs and nasal symptoms on QoL
compared with the Spanish general population
using the SF-36 questionnaire; and (2) to evaluate
the additional impact of mild-moderate nasal
polyposis on QoL in patients with BQs.
Material and methods
Study population: sixty patients with non-cystic
fibrosis BQs in a stable phase of their illnes with
upper airways symptoms were included in this
prospective study from April 2002 to July 2004.
Design: the diagnosis of BQs was based on
symptoms, physical findings, and thoracic high-
resolution CT scan. Stability of the BQs condition
was assessed with a complete clinical evaluation, a
forced spirometry, and if is necessary a thorax
radiology. Stable BQs condition was defined as the
absence of fever, no impairment of airflow limita-
tion, no increase in sputum overproduction or
change of the macroscopic characteristics (puru-
lent), and no increase in chronic cough. In
summary, no increase in respiratory symptoms or
modifications in the treatment over the previous 6
weeks. The day of the study, a complete clinical
evaluation and a forced spirometry (Collins Survey
III, plus, USA) were performed. Exclusion criteria
were hospitalization in the previous 2 months, use
of antibiotics in the last 4 weeks or presence of a
serious concomitant illness.
The diagnosis of nasal polyposis was based on the
visualization of bilateral polyps under nasal endo-
scopic examination. Approval for the study was
obtained from the Ethic’s Committee of our
institution and a signed informed consent was
obtained from all patients.
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The impact of bronchiectasis 1999After a 4-week washout period of oral and
intranasal steroids, all patients with BQs completed
the SF-36 survey. Nasal symptoms and nasal
endoscopy were also scored. Most of experimental
studies and clinical trails investigating nasal poly-
posis consider adequate a washout period of 4
weeks since patients with sinonasal pathology often
follow treatments with oral antihistamines, oral
and intranasal corticosteroids, oral antibiotics, and
nasal lavages that may improve the clinical
symptoms.11,12
Quality of life: the Health Survey SF-36 consists
of 36 self-administered questions and was devel-
oped to measure eight health domains: physical
functioning (PF), role physical (RP), bodily pain
(BP), general health (GH), vitality (VT), role
emotional (RE), social functioning (SF), and mental
health (MH). Two summary scales are also included:
the physical component summary (PCS) and the
mental component summary (MCS). Spanish version
of the SF-36 Health Survey was used. This version is
very similar to the original US questionnaire in
absolute values, age and gender. We needed a
generic questionnaire to assess QoL in pathology
potentially involved both upper and lower airways:
bronchiectasis and sinonasal pathology (with or
without nasal polyposis). Scale scores in each
domain and summaries range from 0 to 100, higher
scores indicating better QoL.13
Nasal symptoms: obstruction, loss of the sense of
smell, rhinorrhea (anterior and posterior), facial
pain, itching, and sneezing was scored. The severity
of nasal symptoms was assessed and scored, follow-
ing the system designed by Rasp et al.,14 and
published before11,12 by our group, as follows: 0, no
symptom; 1, mild but not troublesome symptom; 2,
moderate symptom somewhat troublesome but not
enough to interfere with daily activities or sleep;
and 3, severe and troublesome symptom that
interferes with daily activities or sleep.
Nasal endoscopy: polyp size was scored from 0 to
3 for each nasal cavity following Lildholdt0s
classification: 0, no polyps; 1, mild polyposis (small
polyps not reaching the upper edge of the inferior
turbinate); 2, moderate polyposis (polyps between
the upper and lower edges of the inferior turbi-
nate); 3, severe polyposis (large polyps reaching
the lower edge of the inferior turbinate).15,16 All
patients had upper airway symptoms and were
examined by the same otorhinolaryngologist at the
Department of Otolaryngology of our Hospital.
Lung function: evaluated by forced spirometry
according to standard methods. The best one-
second forced expiratory volume (FEV1) was chosen
for analysis and expressed as percent predicted
FEV1 (FEV1%).Statistical analysis: was performed using SPSS for
Windows (SPSS 11.0, Chicago, IL, USA). All analyses
were performed using two-tailed tests significance
at the 0.05 level. The data are presented as
mean7SD (standard deviation). All data were
assesed for normal distribution and the Bonferroni
correction for multiple comparisons was used. Our
first objective was to investigate the impact of BQs
and nasal symptoms on QoL compared with the
Spanish general population using the SF-36 ques-
tionnaire. A study population size of 29 patients per
group, achieves 95% power to detect a difference
of 20% between the null hypothesis mean of 82.7
(PCS) and the alternative hypothesis mean of 66.4
with an estimated standard deviation of 23.3 and
with a significance level (alpha) of 0.05 using a two-
sided one-sample t-test.
Unpaired Student’s t test was used to compare
nasal symptoms and SF-36 scores of patients with
BQs with those from the Spanish general popula-
tion, and between patients with or without NP. SF-
36 scores for healthy control subjects from the
Spanish population used in comparative analyses
were derived from a sample of 9984 people of
whom 51.8% were females. Males of the Spanish
general population have demonstrated significant
higher scores than females in all SF-36 dimensions.7
After analyzing matching for age, no significant
difference on the mean age between patients of
our study and the Spanish general population.
Pearson correlation coefficients were used to
examine the association between QoL scores and
gender, age, nasal symptoms, nasal polyps, and
lung function. Multiple linear regression analysis
with SF-36 scores were used, alternatively the PCS
and MCS scores as the dependent variable and age,
sex, nasal polyps size as independent variables.
Internal consistency was calculated by Cronbach’s a
coefficient for each SF-36 scale. This coefficient
ranges from 0 to 1, and a minimum coefficient of
0.7 is recommended to ensure a good internal
consistency.17
Results
The mean age of patients with BQs was 52716
years (ranging from 18 to 78 years). Thirty-nine
patients (65%) were female (Table 1). Patients with
BQs scored anterior and posterior rhinorrhea, loss
of the sense of smell, and nasal obstruction as the
major complaints, while itching, facial pain and
sneezing were much less frequent and discomfort-
ing (Table 2).
Twenty-five patients (41.6%) with BQs had nasal
polyps with a size score of 1.570.4 with a range
(1–2).15 The patients distribution by lildholdt is:
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Table 1 Characteristics of patients with bronchiectasis (BQs).
N Age (yr) Gender
(M/F)
Disease
duration (yr)
Smoking habit FEV1% FEV1 FVC
All patients
BQs
60 52716 21/39 1570.7 15 8173.4 2.570.2 8974
BQs without NP 35 55713 9/26 1670.7 6 (5 ex-smokers) 8276 2.870.6 9076.1
BQs with NP 25 48718 12/13 1370.7 9 (7 ex-smokers) 80.674.2 2.370.2 88.476
Table 2 Nasal symptoms in patients with bronchiectasis (BQs).
N Nasal
obstruction
Loss of sense of
smell
Anterior
rhinorrhea
Posterior
rhinorrhea
Sneezing
All patients
with BQs
60 1.6570.9 0.971 1.970.9 1.870.9 1.271
BQs without NP 35 1.470.8 0.570.8 1.870.9 1.970.9 1.270.9
BQs with NP 25 2.0570.8y 1.471.0y 270.8 1.770.9 1.271
Nasal symptoms and polyp size were scored from 0 to 3. yPo0.05, compared to patients with bronchiectasis without nasal
polyposis.
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Figure 1 Quality of life in patients with bronchiectasis
and sinonasal disease compared to the Spanish general
population. Physical functioning (PF), role physical
functioning (RP), bodily pain (BP), general health (GH),
vitality (VT), social functioning (SF), role emotional
functioning (RE), mental health (MH), mental component
summary (MCS), and physical component summary (PCS).
All patients (with and without polyps) had significantly
worse scores in all SF-36 domains. Unpaired student’s t
test was used, *Po0.05.
J.M. Guilemany et al.2000Lildholdt 1: 8 patients; Lildholdt 1.5: 10 patients
(a NP punctuation of 2 in a fossa and 1 in the other);
Lildholdt 2: 7 patients. Patients with BQ and NP
had higher scores (Po0.05) of nasal obstruction
and loss of sense of smell than patients with BQ
without NP.
In comparison with the Spanish general popula-
tion,8 patients with BQs had significantly (Po0.05)
worse QoL scores in all SF-36 domains (Fig. 1) as
well as in MCS and PCS (Table 3). No significant
differences on QoL of patients with BQs and NP or
without NP were observed.
Females showed lower physical functioning (dif-
ference: 13.1, Po0.05 and 95%CI: 1.7–24.5), and
lower social functioning (difference: 15.7, Po0.05
and 95%CI: 0.4–31) than males. Females with
BQs had lower scores of QoL (Po0.05) than
females from the Spanish general population on
physical functioning, body pain, general health,
vitality, social functioning, and role emotional.
Males with BQs also showed lower scores of QoL
(Po0.05) than males from the Spanish general
population on body pain, general health, and
vitality. No significant differences were observed
between males and females on age, pulmonary
function, presence of nasal polyps, upper airway
symptoms, tobacco smoking history, and disease
duration. Analysis of internal consistencies for all
SF-36 domains showed a Cronbach’s a value higher
than 0.7 (0.75–0.91). Age, nasal symptoms, and
polyp size score were not statistically correlated to
SF-36 scores.Patients showed a degree of pulmonary function
impairment on the FEV1% (8173.4). There were no
significant correlation between the two QoL sum-
maries and the degree of pulmonary function are:
SCF (r: 0.21; P ¼ 0:242) and SCM (r: 0.095;
P ¼ 0:599). Multiple linear regression analysis with
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Table 3 Quality of life domains and summary data of patients with bronchiectasis and sinonasal disease.
Spanish general population7 All patients with BQs
Physical functioning (PF) 90.3717.1 76722
Role physical (RP) 87.6730.4 71742
Body pain (BP) 81.9726 62.3724.9
General health (GH) 70.9719.6 35.5718
Vitality (VT) 71.6721 48.7717.3
Role emotional (RE) 94.6721.8 71.3742.5
Social functioning (SF) 94.1715.6 75.2728.3
Mental health (MH) 77.7718.7 65.4721.4
Physical component summary (PCS) 82.7723.3 46.5726.7
Mental component summary (MCS) 84.5719.3 39.7727.3
Po0.05 bronchiectasis with nasal pathology compared to the Spanish general population.
The impact of bronchiectasis 2001SF-36 scores were used, alternatively the PCS and
MCS scores as the dependent variable and age, sex,
nasal polyps size as independent variables without
significant results.Discussion
No studies have reported the impact of BQ and
upper airway disease on QoL using the SF-36
questionnaire. The main findings of our study were:
(1) patients with BQ have an impaired QoL when
compared to the Spanish general population; (2)
nasal polyposis has no additional impact on QoL in
patients with BQs.
This study demonstrates that QoL in patients with
BQ is impaired compared to the general populations
in all SF-36 domains. No associations between QoL
and age, nasal symptoms, and polyp size were
observed. Furthermore, our findings supported the
developer’s claim of internal consistency for the SF-
36 questionnaire since all the coefficients were at
values above those recommended.
This study also demonstrates that women with
BQ report poorer QoL scores on physical functioning
and social functioning than males. Using the SF-36
questionnaire, Bousquet et al. have observed that
males with asthma report higher QoL scores than
females with asthma.18 Gender-related differences
in response to a chronic disease such as asthma is
important in tailoring an education and manage-
ment plan to each individual patient.19 Allergic
rhinitis and asthma usually coexist. Patients with
both diseases experience more physical limitations
than patients with allergic rhinitis alone, but no
differences were found between these two groups
for concepts related to social/mental health.20
Cystic fibrosis is the most common autosomal
recessive disease with fatal outcome in Caucasiansdue to chronic infection of the lung resulting in
fibrosis and bronchiectasis followed by respiratory
insufficiency. Some differences emerged between
males and females, with females generally report-
ing poorer QoL scores. Evidence indicated that
males and females perceived their health status
differently, with females having a more accurate
perception of objective clinical health status.21
The St. George Respiratory Questionnaire (SGRQ)
is a self-administrated health-related QoL measure
containing 50 items and 76 weighted responses
divided into three components: symptoms, activity,
and impacts. The SGRQ has been used to assess the
QoL in patients with asthma, COPD, a1-antitrypsin
deficiency,22–25 and more recently BQ.26 Anxiety
and depression are quite common in patients with
BQ.27 QoL measured by the SGRQ in patients with
BQ assessing the pulmonary function and the
presence of colonization (with pseudomonas or
other microorganisms) shows that patients with BQ
colonized with pseudomonas have worse pulmonary
function and QoL than uncolonized patients. More-
over, patients having microorganisms other than
pseudomonas have a worse QoL than those without
microorganisms.28 Pseudomonas aeruginosa is the
most relevant pathogen producing chronic lung
infections in patients with chronic underlying
diseases such as cystic fibrosis (CF), bronchiectasis,
and chronic obstructive pulmonary disease (COPD).
Hypermutation of pseudomona is found to be a key
factor for the development of multiple-antimicro-
bial resistance, and therefore these findings are
expected to have important consequences for the
treatment of chronic infections.29,30
Chronic rhinosinusitis (CRS) is an inflammatory
disease of the mucosa of the nasal cavity and
paranasal sinuses with symptoms lasting longer
than 12 weeks. Currently, it is unclear, whether
CRS with NP and CRS without NP represent different
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J.M. Guilemany et al.2002disease entities or just different stages of one
single disease. Recent evidence suggests that,
despite clinical similarities, CRS with and without
NP have different inflammatory pathways and
cytokine profiles. Although the similar clinical
symptoms found in these patients, the great
clinical differences probably remains in the inten-
sity on nasal obstruction and smell disorders.31
Nasal polyps are often an indicative of airway
disease involving both the upper and lower respira-
tory tracts.32 Radenne et al.33 has investigated the
impact of NP in QoL demonstrating that nasal polyps
impaired QoL in all SF-36 domains. More recently our
group demonstrated that asthma but not aspirin
sensitivity has an additional negative impact on the
QoL of patients with NP.11 QoL improved after NP
treatment, the improvement being related to nasal
symptoms. Both medical and surgical treatment led
to similar effects in improving QoL.12,34 Gliklich and
Metson35 assessed the burden of chronic rhinosinusitis
by using the SF-36 questionnaire and demonstrated a
significant decrease in body pain, general health,
vitality, and social functioning domains compared
with the American general population. Using the SF-
36, other studies have also demonstrated that
chronic rhinosinusitis has a considerable impact on
all SF-36 domains except for physical functioning and
compared with a healthy population.36–38
Patients with NP had lower scores in all SF-36
domains except for physical functioning and role
emotional than patients with coronary artery
disease,39 chronic obstructive pulmonary disease,9
and asthma.40
In the present study patients with BQ and mild-
moderate NP (Lildholdt classificationo1.5), showed
no further negative impact on QoL. The three most
disabling symptoms were anterior rhinorrhea, pos-
terior rhinorrhea and nasal obstruction. This study
provides additional evidence that the degree of
abnormality on nasal symptoms is not associated
with impairment of QoL. Patients with nasal polyps
had a higher nasal obstruction and loss of sense of
smell that did provoke no significant differences on
QoL compared to patients without NP.
In conclusion, these results suggest that BQ has a
considerable impact on QoL, but that nasal polyps
have no additional impact on QoL of patients with
BQ. Further studies are needed to better under-
standing of the association between the upper and
lower airways diseases.
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